DS 7423

Drug Profile

DS 7423

Alternative Names: DS-7423

Latest Information Update: 24 May 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Inc
  • Class Antineoplastics
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2013 Daiichi Sankyo completes a phase I trial in Solid tumours in USA (NCT01364844)
  • 01 Apr 2012 Phase-I clinical trials in Solid tumours in Japan (PO) (JapicCTI-121766)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top